Last year the United States Congress beefed up its food and drug safety legislation to increase the number of products that will be regulated as pharmaceuticals by the U.S. Food and Drug Administration (FDA). The new regulations are still being developed but the determinations and decisions are coming.
In February, the FDA sent a warning letter to the Pompeian company regarding what they refer to as the “misbranding” of “Pompeian Imported Extra Light Olive Oil”. Here is part of the determination from the letter:
“Based on claims made on your website, www.pompeian.com, we have determined that the product “Pompeian Imported Extra Light Olive Oil” is promoted for conditions that cause the product to be a drug under section 201(g)(1) of the Act [21 USC § 321(g)(1)]. The therapeutic claims on your website establish that the product is a drug because it is intended for use in the cure, mitigation, treatment, or prevention of disease. The marketing of this product with these claims violates the Act.”
Even though, the United States Department of Agriculture (USDA) has lax olive oil standards, see my article, “Olive Oil Standards Get a Facelift“, strict standards and regulations for domestic producers and olive oil importers regarding labelling and representation of content will come through the FDA.
This is an issue that I am going to be following more rigorously. It is a game changer.
May the sun shine through your branches.